imu-recherche

Home < Research < P. Meylan

A. Telenti

	P. Meylan

D. Sanglard

S. Kunz

A. Ciuffi

A. Coste

G. Greub

P. Hauser

D. Blanc

P.-Y. Bochud

D. Moradpour

D. Nardelli

Répondant du site:
imu.info@chuv.ch

Pascal Meylan Lab

Pascal Meylan, MD, Associate Professor
++41 (0)21 314 4098
++41 (0)79 556 0682
pascal.meylan@chuv.ch

Research topics

Management of infections in transplant patients

Transplants patients are at increased risk of infections, due the the invasive procedures they undergo, and the immunosuppressive they receive to prevent rejection.

Among those infections, Cytomegalovirus (CMV) used to be the #1 cause for morbidity and mortality in transplants patients. Over the years, the development of antivirals with activity against CMV, and their use, to treat established infection, or more recently to prevent the appearance of disease (preemptive approach) or infection altogether (prophylactic approach) has greatly improved the immediate prognosis of CMV infection. The identification of risk factors for severe or protracted CMV infection helps redirect resources toward the high risk patients.

Outstanding problems are the replacement of intravenous drugs by orally available drugs (pharmakokinetic and pharmakodynamic validation of valganciclovir), the fine tuning of the doses and duration of prophylactic regimens, the problem of delayed CMV infection and disease, observed in some patients after their prophylactic regimen is discontinued, as well as the role of CMV in the pathogenesis of chronic allograft injury.

These problems are addressed in collaboration with colleagues from the Centre de Transplantation d’organes and the Division de Pharmacologie clinique. In addition, we have participated to the launch, on May 1st 2008 of the Swiss Transplant Cohort Study (supported by the SNF), a tool in which we are currently organizing CMV intervention studies as well as studies of the role of innate immunity in the course of CMV infection.

In our responsability for diagnostic virology, we regularly meet clinically related problems that provide opportunities of studies with our Infectious Disease colleagues, e.g. role of molecular diagnostic tools in the management of viral meningitis, or the clinical impact of diagnosing respiratory viruses.

Current lab members
Name	Position	Contact
Noémie Boillat-Blanco	MD, Fellow in Infectious Diseases	Noemie.boillat@chuv.ch
Odile Devanthéry	Medical Student	Odile.Devanthery@unil.ch

Selected publications

2008
1:	Carron PN, Yerly S, Ksontini R, Meylan P, Calandra T.
		[Pyoderma gangrenosum: diagnostic and therapeutic challenge] Rev Med Suisse. 2008 Sep 10;4(170):1938-40, 1942-3.
2:	Fontana-Binard L, Schultze D, Rojanavisut BS, Krüger DH, Dollenmaier G, Zanetti G, Meylan P.
		[First case of nephropathia epidemica acquired in Switzerland] Rev Med Suisse. 2008 Jun 25;4(163):1572-5.
3:	Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, Kleeberg J, Le Goff G, Pantaleo G, Du Pasquier RA.
		Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain. 2008 Jul;131(Pt 7):1712-21.
4:	Lamoth F, Jayet PY, Aubert JD, Rotman S, Mottet C, Sahli R, Lautenschlager I, Pascual M, Meylan P.
		Case report: human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. J Med Virol. 2008 Oct;80(10):1804-7.
5:	Lamoth F, Manuel O, Venetz JP, Faouzi M, Meylan P, Pascual M.
		What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation? Transplantation. 2008 Nov 15;86(9):1323-4.
6:	Leung Ki EL, Venetz JP, Meylan P, Lamoth F, Ruiz J, Pascual M.
		Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. Clin Transplant. 2008 Mar-Apr;22(2):245-9
7:	Meylan P, Vollenweider P, Gianinazzi F, Monti M.
		[Varicella pneumonia] Praxis (Bern 1994). 2008 Sep 24;97(19):1037-43.
8:	Perrottet N, Robatel C, Meylan P, Pascual M, Venetz JP, Aubert JD, Berger MM, Decosterd LA, Buclin T.
		Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. J Antimicrob Chemother. 2008 Jun;61(6):1332-5.
9:	Wasserfallen JB, Kast-Brückner M, Manuel O, Venetz JP, Meylan PR, Pascual M.
		Cost-effectiveness of a new combined immunosuppressive and anti-infectious regimen in kidney transplantation. Int J Technol Assess Health Care. 2008 Summer;24(3):312-7.
2007
1:	Jilek S, Kuhle J, Meylan P, Reichhart MD, Pantaleo G, Du Pasquier RA.
		Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. J Neuroimmunol. 2007 Dec;192(1-2):192-7.
2:	Manuel O, Meylan PR, Rotman S, Fontana M, Moradpour D, Pascual M.
		Oral valganciclovir for cytomegalovirus colitis after liver transplantation. Transplantation. 2007 Jan 27;83(2):239-40.
3:	Manuel O, Pascual M, Trendelenburg M, Meylan PR.
		Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation. 2007 Feb 15;83(3):359-62.
4:	Manuel O, Tarr PE, Venetz JP, Trendelenburg M, Meylan PR, Pascual M.
		Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. Transpl Infect Dis. 2007 Sep;9(3):214-8.
5:	Manuel O, Venetz JP, Fellay J, Wasserfallen JB, Sturzenegger N, Fontana M, Matter M, Meylan PR, Pascual M.
		Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly. 2007 Dec 1;137(47-48):669-76.
6:	Meylan PR, Aubert JD, Kaiser L.
		Influenza transmission to recipient through lung transplantation. Transpl Infect Dis. 2007 Mar;9(1):55-7.
7:	Meylan S, Robert D, Estrade C, Grimbuehler V, Péter O, Meylan PR, Sahli R.
		Real-time PCR for type-specific identification of herpes simplex in clinical samples: evaluation of type-specific results in the context of CNS diseases. J Clin Virol. 2008 Feb;41(2):87-91.
8:	Perrottet N, Beguin A, Meylan P, Pascual M, Manuel O, Buclin T, Biollaz J, Decosterd LA.
		Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):420-9.
2006
1:	Loeuillet C, Martinon F, Perez C, Munoz M, Thome M, Meylan PR.
		Mycobacterium tuberculosis Subverts Innate Immunity to Evade Specific Effectors. J Immunol, 2006 ;177:6245-55.
2:	Manuel O, Pascual M, Trendelenburg M, Meylan P.
		Association between mannose-binding lectin deficiency and Cytomegalovirus infection after kidney transplantation. Transplantation. 2007 Feb 15;83(3):359-62.
3:	Meylan P, Aubert, J-D, and Kaiser L.
		Influenza transmission to recipient through lung transplantation. Transpl Infect Dis. 2007 Mar;9(1):55-7
4:	Meylan PRA and Pascual M.
		Preemptive versus prophylactic approach in the management of CMV in solid organ transplant recipients: what we know and what we do not know (Editorial comment). Clin Infect Dis, 2006 ;43:881-3.
5:	de Valliere S, Cometta A, Zimmermann H, Vaudaux B, Meylan P.
		Evidence of new foci of tick-borne encephalitis in the French speaking part of Switzerland Rev Med Suisse. 2006 Sep 27;2(80):2189, 2191-4.
2005
1:	Fellay J, Venetz JP, Pascual M, Aubert JD, Seydoux C, Meylan PR.
		Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Am J Transplant. 2005 Jul;5(7):1781-2.
2:	Meylan P. et The Swiss Herpes Management Forum.
		Swiss recommendations for the management of genital herpes and herpes simplex virus infection of the neonate. Rev Med Suisse. 2005;1:2315.
3:	Oddo M, T Calandra, R Bucala, and PRA Meylan.
		Role of Migration Inhibitory Factor (MIF) as a macrophage arming factor for human macrophages against Mycobacterium tuberculosis. Infect Immun 2005 ;73:3783-6.

Last Update on 24.08.2010 - Publication credits - Legal information

Search